Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of software for
discovery and development, announced that The Dow Chemical Company
(NYSE: DOW) has licensed both its best-in-class GastroPlus™
and ADMET
Predictor™ software programs.
John DiBella, vice president of marketing and sales for Simulations
Plus, said, “Dow again demonstrates its foresight by incorporating our
modeling and simulation technology to assist with their toxicology and
environmental research activities. There is an appreciation for how the
tight integration of our Quantitative Structure-Activity Relationship
(QSAR) and Physiologically-Based Pharmacokinetic (PBPK) modeling tools
streamline the process of generating in vivo simulation results
through different administration routes. We look forward to working with
Dow scientists in these areas and identifying potential areas for
collaboration. This announcement, following closely on the news that the
U.S. EPA has added licenses of our software, provides further evidence
that our programs have applications across several industries.”
About Dow
Dow (NYSE: DOW) combines the power of science and technology to
passionately innovate what is essential to human progress. The Company
is driving innovations that extract value from the intersection of
chemical, physical and biological sciences to help address many of the
world's most challenging problems such as the need for clean water,
clean energy generation and conservation, and increasing agricultural
productivity. Dow's integrated, market-driven, industry-leading
portfolio of specialty chemical, advanced materials, agrosciences and
plastics businesses delivers a broad range of technology-based products
and solutions to customers in approximately 180 countries and in high
growth sectors such as packaging, electronics, water, coatings and
agriculture. In 2013, Dow had annual sales of more than $57 billion and
employed approximately 53,000 people worldwide. The Company's more than
6,000 products are manufactured at 201 sites in 36 countries across the
globe. References to "Dow" or the "Company" mean The Dow Chemical
Company and its consolidated subsidiaries unless otherwise expressly
noted. More information about Dow can be found at www.dow.com.
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of groundbreaking drug
discovery and development simulation and modeling software, which is
licensed to and used in the conduct of research by major pharmaceutical,
biotechnology, chemical, and food industry companies worldwide.
Simulations Plus, Inc., is headquartered in Southern California and
trades on the NASDAQ Capital Market under the symbol “SLP.” For more
information, visit our Web site at www.simulations-plus.com.
Safe Harbor Statement Under the Private Securities Litigation Reform
Act of 1995 – With the exception of historical information, the
matters discussed in this press release are forward-looking statements
that involve a number of risks and uncertainties. Words like “believe,”
“expect” and “anticipate” mean that these are our best estimates as of
this writing, but that there can be no assurances that expected or
anticipated results or events will actually take place, so our actual
future results could differ significantly from those statements. Factors
that could cause or contribute to such differences include, but are not
limited to: our ability to maintain our competitive advantages,
acceptance of new software and improved versions of our existing
software by our customers, the general economics of the pharmaceutical
industry, our ability to finance growth, our ability to continue to
attract and retain highly qualified technical staff, our ability to
identify and close acquisitions on terms favorable to the Company, and a
sustainable market. Further information on our risk factors is contained
in our quarterly and annual reports as filed with the Securities and
Exchange Commission.
Copyright Business Wire 2014